8-K current report · filed Nov 16, 2026

ANI PHARMACEUTICALS INC (ANIP) 8-K Current Report: November 16, 2026

Item 7.01Item EX-99.1ANIP overview

Short answer

ANI PHARMACEUTICALS INC (ANIP) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Updated investor presentation published November 16, 2026.

ANI PHARMACEUTICALS INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Updated investor presentation published November 16, 2026
  • Materials intended for investor and analyst meetings
  • Exhibit 99.1 contains the presentation and may include updated company outlook or strategy័ត៌មាន

Item EX-99.1 · Exhibit EX-99.1

  • 2026 guidance: revenue $1.085B-$1.125B, adjusted EBITDA $290M-$300M, adjusted EPS $9.37-$9.71
  • Rare Disease expected to exceed 50% of 2026 revenue, accelerating ANI’s shift away from generics
  • Cortrophin Gel guidance $480M-$500M, supported by gout expansion and a salesforce increase from ~120 to ~180 representatives
  • Egetis acquisition would add EMCITATE, the only approved MCT8 treatment, with over $300M peak-sales potential
  • Acquisition execution and commercialization remain key risks, while $420.8M cash and 0.7x net leverage provide financial flexibility

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ANI PHARMACEUTICALS INC 8-K filings

Get the next ANIP 8-K as it lands

Follow ANIP for push alerts, or ask the research agent what this filing means.